BioAge Labs, Inc. BIOA
Updated: 19 Jun 2026
No signal published yet
We already track BioAge Labs and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow BioAge Labs, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow BioAge Labs free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On June 16, 2026, BioAge announced that the first participant was dosed in the Phase 2 QUELL-CV trial evaluating BGE-102 in patients with obesity and elevated cardiovascular risk. Topline data from the trial is anticipated in the second half of 2026.
What Firelda Watch includes for BioAge Labs, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow BioAge Labs, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow BioAge Labs free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more